Cargando…

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. PATIENTS AND METHODS: R-HCC patients who underwent T...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yusheng, Ren, Yanqiao, Chen, Lei, Sun, Tao, Zhang, Weihua, Sun, Bo, Zhu, Licheng, Xiong, Fu, Zheng, Chuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922827/
https://www.ncbi.nlm.nih.gov/pubmed/35287627
http://dx.doi.org/10.1186/s12885-022-09325-6
_version_ 1784669572598595584
author Guo, Yusheng
Ren, Yanqiao
Chen, Lei
Sun, Tao
Zhang, Weihua
Sun, Bo
Zhu, Licheng
Xiong, Fu
Zheng, Chuansheng
author_facet Guo, Yusheng
Ren, Yanqiao
Chen, Lei
Sun, Tao
Zhang, Weihua
Sun, Bo
Zhu, Licheng
Xiong, Fu
Zheng, Chuansheng
author_sort Guo, Yusheng
collection PubMed
description PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. PATIENTS AND METHODS: R-HCC patients who underwent TACE plus camrelizumab or TACE-alone from January 2016 to August 2021 were retrospectively evaluated. Patients were assessed for tumor response, progression-free survival, survival rates and adverse events. RESULTS: Seventy-one patients were included in this study, including 20 patients in the TACE- camrelizumab group and 51 patients in the TACE-alone group. The objective response rate was 56.9% in the TACE-alone group and 40% in the TACE-camrelizumab group at 3 months (P = 0.201). The disease control rates were 84.3% in TACE-alone group and 80% in TACE-camrelizumab group at 3 months (P = 0.663). The progression-free survival (PFS) of the TACE-alone group was slightly longer than those of the TACE- camrelizumab group (9 months vs. 6 months). However, there were no statistically significant differences in the median PFS (P = 0.586). Similarly, there were no significant differences in the half-year and one-year survival rates (P = 0.304, P = 0.430). Multivariate analysis revealed that Neutrophil-to-lymphocyte ratio (NLR) was associated with PFS significantly. 75% patients developed at least one type of AEs related to camrelizumab in TACE-camrelizumab group, and no patients developed severe AEs. CONCLUSION: Comparing with TACE-Alone, the efficacy of TACE-camrelizumab for patients with R-HCC was similar. Meanwhile, the results of this study also indicated that TACE is still a better choice for patients with R-HCC.
format Online
Article
Text
id pubmed-8922827
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89228272022-03-22 Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma Guo, Yusheng Ren, Yanqiao Chen, Lei Sun, Tao Zhang, Weihua Sun, Bo Zhu, Licheng Xiong, Fu Zheng, Chuansheng BMC Cancer Research PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. PATIENTS AND METHODS: R-HCC patients who underwent TACE plus camrelizumab or TACE-alone from January 2016 to August 2021 were retrospectively evaluated. Patients were assessed for tumor response, progression-free survival, survival rates and adverse events. RESULTS: Seventy-one patients were included in this study, including 20 patients in the TACE- camrelizumab group and 51 patients in the TACE-alone group. The objective response rate was 56.9% in the TACE-alone group and 40% in the TACE-camrelizumab group at 3 months (P = 0.201). The disease control rates were 84.3% in TACE-alone group and 80% in TACE-camrelizumab group at 3 months (P = 0.663). The progression-free survival (PFS) of the TACE-alone group was slightly longer than those of the TACE- camrelizumab group (9 months vs. 6 months). However, there were no statistically significant differences in the median PFS (P = 0.586). Similarly, there were no significant differences in the half-year and one-year survival rates (P = 0.304, P = 0.430). Multivariate analysis revealed that Neutrophil-to-lymphocyte ratio (NLR) was associated with PFS significantly. 75% patients developed at least one type of AEs related to camrelizumab in TACE-camrelizumab group, and no patients developed severe AEs. CONCLUSION: Comparing with TACE-Alone, the efficacy of TACE-camrelizumab for patients with R-HCC was similar. Meanwhile, the results of this study also indicated that TACE is still a better choice for patients with R-HCC. BioMed Central 2022-03-14 /pmc/articles/PMC8922827/ /pubmed/35287627 http://dx.doi.org/10.1186/s12885-022-09325-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Guo, Yusheng
Ren, Yanqiao
Chen, Lei
Sun, Tao
Zhang, Weihua
Sun, Bo
Zhu, Licheng
Xiong, Fu
Zheng, Chuansheng
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
title Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
title_full Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
title_fullStr Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
title_full_unstemmed Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
title_short Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
title_sort transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922827/
https://www.ncbi.nlm.nih.gov/pubmed/35287627
http://dx.doi.org/10.1186/s12885-022-09325-6
work_keys_str_mv AT guoyusheng transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT renyanqiao transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT chenlei transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT suntao transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT zhangweihua transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT sunbo transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT zhulicheng transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT xiongfu transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma
AT zhengchuansheng transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma